VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

TMates Weightloss Semaglutide reviews reveal how users are losing weight with this telehealth prescription service—see if it ...

"The medication's going to be 50 percent of your journey, and the other 50 percent is still what you choose to eat and the ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs for millions of people.

Ozempic may have serious side effects, including thyroid cancer and problems with the pancreas, gallbladder, kidneys, and ...

Some less expensive versions of popular weight loss drugs are no longer available to patients, after the Food & Drug ...

Trend alert! Split dosing, stretch dosing, skip dosing, microdosing Ozempic… People are finding creative ways to use ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.

A man who stopped using Ozempic after shedding 112 pounds has revealed how he's managed to maintain his weight. The drug, ...

Semaglutide manufacturers seem to be taking advantage of America’s health crises to indulge in anticompetitive behavior.